

MONDAY 10 SEPTEMBER

7.30am	Registration, Level 5						
8.30am-11.00am	Opening Ceremony and Plenary: 1 Room: New Zealand 1 and 2, Level 5 Chairs: Edward Gane and John Hornell						
8.30am-9.00am	Powhiri Ngati Whātua, Kaumatua David Hillman (He Kamaka Oranga)						
9.00am-9.15am	Opening address The Hon. Tony Ryall, Health Minister, New Zealand						
9.15am-9.20am	Introduction by Representative of the 2012 Viral Hepatitis Conference Partners Professor Edward Gane, Deputy Director, New Zealand Liver Transplant Unit, Auckland, New Zealand						
9.20am-9.25am	Launch of the AHA Consensus-based Nursing Guidelines for the Care of patients with Liver Disease Ms Sue Mason, President, Australasian Hepatology Association, NSW, Australia						
9.25am-9.30am	Announcement of the Junior Research Award Recipients Professor Greg Dore, Past President, Australasian Society for HIV Medicine, NSW, Australia						
9.30am-10.00am	Health Burden of HBV on the Asia Pacific Region Professor Henry Chan, Director, Cheng Suen Man Shook Centre for Hepatitis Research; Director, Center for Liver Health, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong						
10.00am-10.30am	To trust or not to trust..... that is the question Professor Paul Ward, Head, Discipline of Public Health, School of Medicine, Flinders University, South Australia, SA; Honorary Professor, Centre for Values, Ethics and Law in Medicine (VELiM), University of Sydney, NSW, Australia						
10.30am-11.00am	That's right, women are...different: Sex differences and HCV infection Professor Kimberly Page, Professor in Residence, Epidemiology & Biostatistics Department, University of California, San Francisco, USA						
11.00am-11.30am	Morning Tea in Exhibition and Poster Area, Auckland Rooms, Level 4						
11.30am-1.00pm	Symposium Session: Clinical Care: Innovative models of hepatitis C treatment and care Room: New Zealand 1 Chairs: Greg Dore and Sue Mason	11.30am-1.00pm	Symposium Session: Epidemiology, Public Health and Prevention: Not just counting: Using surveillance and modelling for prevention and management Room: New Zealand 2 Chairs: Margaret Hellard and Christine Selvey	11.30am-1.00pm	Symposium Session: Community and Social Research: Stigma and Discrimination – Looking for Answers in all the right places Room: New Zealand 3 Chairs: Suzanne Fraser and Tiia Harrison	11.30am-1.00pm	Symposium Session: Basic Science: New Technologies Room: New Zealand 4 Chairs: William Abbott and Eric Gowans
11.30am-11.42am	Enhancing treatment for hepatitis C in opioid substitution settings: The ETHOS Study Paul Haber, Head, Drug and Alcohol Services, Royal Prince Alfred Hospital, Camperdown NSW, Australia	11.30am-11.45am	Chronic hepatitis in New Zealand: Long-term surveillance, does it work? John Hornell, CEO, The Hepatitis Foundation of New Zealand, Tauranga, New Zealand	11.30am-11.50am	Trust and stigma: Exploring the inter-relations and implications for policy and practice Paul Ward, Head, Discipline of Public Health, School of Medicine, Flinders University, South Australia; Honorary Professor, Centre for Values, Ethics and Law in Medicine, (VELiM), University of Sydney	11.30am-11.55am	The use of next generation sequencing to understand the host-viral interplay Silvana Gaudieri, Associate Professor, School of Anatomy and Human Biology, University of Western Australia, WA, Australia
11.42am-11.54am	Hepatitis C treatment initiation in primary care: Preliminary results David Baker, GP, East Sydney Doctors, Sydney, NSW, Australia	11.45am-12.00pm	Count on it; new approaches to value-adding HBV surveillance in Australia Benjamin Cowie, Epidemiologist & Physician, VIDRL / VIDS, Melbourne Health, Melbourne, VIC, Australia	11.50am-12.10pm	Stigma, the heart of darkness Jude Byrne, Senior Project Manager, Australian Injecting and Illicit Drug Users League (AIVL), Canberra, ACT, Australia	11.55am-12.20pm	Application of next-generation sequencing technologies to study viral hepatitis: From bioinformatics to vaccine development Fabio Luciani, Research Fellow, University of NSW, Sydney, NSW, Australia

MONDAY 10 SEPTEMBER

11.54am-12.06pm	Pilot for a community-based assessment and support programme for hepatitis C Kelly Barclay, Project Manager, The Hepatitis Foundation of New Zealand, Tauranga, New Zealand	12.00pm-12.15pm	The complexity of hepatitis C epidemiology and transmission demands new and innovative surveillance responses Mark Stoove, Head, HIV/STI Research Group, Burnet Institute, Melbourne, VIC, Australia	12.10pm-12.30pm	Sexual transmission of hepatitis C, designing a resource that raises awareness without creating stigma Rhondda Lewis Health Promotion Officer, Viral Hepatitis, Cairns Sexual Health Service, Cairns, QLD, Australia	12.20pm-12.45pm	Dynamic imaging of hepatitis C virus replication and assembly Michael Beard, NHMRC Senior Research Fellow, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, Australia
12.06pm-12.18pm	A nurse-led outreach program for assessment and treatment of chronic hepatitis C via tele-medicine in the prison setting Jacqueline Clegg, Clinical Nurse Consultant - Hepatitis, Justice Health and Forensic Mental Health Network, NSW, Australia						
12.18pm-12.30pm	Makes you want to do treatment: Increasing treatment readiness among clients of a hepatitis C community clinic in Christchurch, New Zealand Carla Treloar, Deputy Director, National Centre In HIV Social Research, Sydney, NSW, Australia	12.15pm-12.30pm	Monitoring Hepatitis C and Associated Risk Behaviour in People who Inject Drugs: The Australian Needle and Syringe Program Survey (ANSPS) Lisa Maher, Program Head, Viral Hepatitis Epidemiology and Prevention Program, Kirby Institute for Infection and Immunity, Sydney, NSW, Australia	12.30pm-12.50pm	My Blood is Always Red Heath Te Au, Trainee Counsellor, Care New Zealand, Milton, New Zealand	12.45pm-1.00pm	Discussion
12.30pm-1.00pm	Panel Discussion Greg Dore, Paul Haber, David Baker, Kelly Barklay, Carla Treloar, Annie Madden, Janet Catt	12.30pm-1.00pm	Panel Discussion John Hornell, Benjamin Cowie, Mark Stoove, Lisa Maher, Nicole Wiggins	12.50pm-1.00pm	Discussion		
1.00pm-2.30pm	Lunch in Exhibition and Poster Area, Auckland Rooms, Level 4						
1.15pm-2.30pm	Satellite Session: Roche Diagnostics - Expanding frontiers for effective management of chronic hepatitis Room: New Zealand 1 Chair: Dominic Ray-Chadhuri			1.15pm-1.45pm	Satellite Session: 'Afternoons With Max Marshall' - a short film exploring drugs, discrimination and the media Room: New Zealand 3 Chairs: Jude Byrne and Annie Madden		
1.15pm-1.20pm	Opening remarks Dr Dominic Ray-Chadhuri						
1.20pm-1.40pm	HCV RNA quantitation with new DAAs Professor Edward Gane, Deputy Director, New Zealand Liver Transplant Unit, Auckland, New Zealand						
1.40pm-2.00pm	Utility of HBsAg and HBV DNA quantitation Professor Henry Chan, Director, Cheng Suen Man Shook Centre for Hepatitis Research. Director, Center for Liver Health, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong						
2.00pm-2.15pm	Diagnostics assays optimised for clinical decision making Mrs Ahila Padmanathan, Regional Manager Asia Pacific, Medical & Scientific Affairs, Roche Diagnostics, Petaling Jaya, Malaysia						
2.15pm-2.30pm	Q & A and Closing Remarks from the Chair						

MONDAY 10 SEPTEMBER

2.30pm-4.00pm	Proffered Paper Session: Clinical Care: Hepatitis B treatment: Advances in understanding	2.30pm-4.00pm	Proffered Paper Session: Epidemiology, Public Health and Prevention: Hepatitis C incidence, harm reduction, and treatment: Population approaches?	2.30pm-4.00pm	Proffered Paper Session: Community and Social Research: HCV Models of Care – Reflections on Research	2.30pm-4.00pm	Proffered Paper Session: Basic Science: Influence of host and virus on infection outcome
	Room: New Zealand 1 Chairs: Frank Weilert and James Fung		Room: New Zealand 2 Chairs: Lisa Maher and Mark Stooove		Room: New Zealand 3 Chairs: Helen Tyrrell and Paul Ward		Room: New Zealand 4 Chairs: Michael Beard and Fabio Luciani
2.30pm-2.45pm	Serologic and clinical outcomes of horizontally acquired chronic hepatitis B infection in NZ Maori: Results from a 27-year follow up study Tien Huey Lim	2.30pm-2.45pm	High but declining HCV incidence in people who inject drugs in Sydney, Australia Lisa Maher	2.30pm-2.45pm	Shaken not deterred: the Christchurch Hepatitis C Community Clinic Jenny Bourke	2.30pm-2.45pm	Characterising Hepatitis B in Northern Australia by Molecular Epidemiology - The CHARM NT Study Jane Davies
2.45pm-3.00pm	Entecavir in chronic hepatitis B “real world” experience at Auckland City Hospital Alex Lampen-Smith	2.45pm-3.00pm	Impact of disclosure of Hepatitis C virus infection on injecting frequency and behaviour in a network of people who inject drugs Rachel Sacks-Davis	2.45pm-3.00pm	Providing hepatitis C care and treatment in opiate substitution settings: A qualitative evaluation of four ETHOS sites Jake Rance	2.45pm-3.00pm	Characterisation of IFN-lambda producing cells in chronic HCV infection Jeffrey Smith
3.00pm-3.15pm	Adherence to hepatitis B virus anti-viral therapies Suzanne Polis	3.00pm-3.15pm	Quantifying the fraction of cirrhosis attributable to alcohol among patients chronically infected with hepatitis C: Implications for treatment cost-effectiveness studies Sharon Hutchinson	3.00pm-3.15pm	Increasing Attendance for Hepatitis C Care: Service Delivery Models that Attract Clients Sandi Mitchell	3.00pm-3.15pm	Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus Vincent Pederagnana
3.15pm-3.30pm	Perinatal management of hepatitis B positive mothers and their infants Jing Dong	3.15pm-3.30pm	Behavioural sequelae of hepatitis C screening and infection disclosure among active injection drug users: A longitudinal study Julie Bruneau	3.15pm-3.30pm	Acceptability of psychological support in Australians living with chronic hepatitis C Benjamin Stewart	3.15pm-3.30pm	IL28B SNP RS12979860 genotyping of Hepatitis C patients in New Zealand Neil Van de Water
3.30pm-3.45pm	Antiviral treatment of chronic HBV infection in remote-dwelling Aboriginal patients in Australia's Northern Territory Suresh Sharma	3.30pm-3.45pm	Association between harm reduction intervention uptake and HCV prevalence and incidence among injecting drug users attending sites that provide sterile injecting equipment in Scotland Sharon Hutchinson	3.30pm-3.45pm	We ask questions, but are we asking the right questions? Fiona Poeder	3.30pm-3.45pm	Plasma IP10 level predicts spontaneous clearance in acute HCV infection independent of IL28B genotype Jason Grebely
3.45pm-4.00pm	Chronic Hepatitis B: An Exploration of Current Awareness and Practice in Primary Health Care in North Queensland Yvonne Drazic	3.45pm-4.00pm	Assessment and treatment of hepatitis c virus infection among people who inject drugs in the opioid substitution setting: The ETHOS Study Maryam Alavi	3.45pm-4.00pm	Redesigning responsibility: Hepatitis C prevention in sexual partnerships Suzanne Fraser	3.45pm-4.00pm	IL28B genotype is associated with intraphepatic interferon stimulated gene expression in HCV genotype 1 but not genotype 3 infection Alex Thompson
4.00pm-4.30pm	Afternoon Tea in Exhibition and Poster Area, Auckland Rooms, Level 4						

MONDAY 10 SEPTEMBER

4.30pm-6.20pm	Conference Plenary: 2 Room: New Zealand 1 and 2 Chairs: Annie Madden and Charles Henderson
4.30pm-5.00pm	The Social Context of Anti-Viral Treatment Engagement: The Making of Patient Citizenship in the Treatment of HCV and HIV Professor Tim Rhodes, Professor of Public Health Sociology and Director of the Centre for Research on Drugs and Health Behaviour, London School of Hygiene and Tropical Medicine, England
5.00pm-5.30pm	Hepatitis B and Maori Health - Engaging with the future Professor Chris Cunningham, Professor & Director, Research Centre for Māori Health & Development, Massey University, Wellington, New Zealand
5.30pm-6.00pm	The riddle of HCV persistence; early interactions between genomic RNA and cell defence mechanisms Professor Peter Simmonds, Professor of Virology, Centre for Infectious Diseases, University of Edinburgh, Edinburgh, Scotland
6.00pm-6.05pm	Launch of the First Australian Hepatitis B Testing Policy Dr Scott Bowden – Head, Molecular Microbiology Laboratory, Victorian Infectious Diseases Reference Laboratory (VIDRL) and Assoc Prof, Department of Microbiology, Monash University, Melbourne, VIC, Australia
6.05pm-6.20pm	Auckland Statement
6.20pm-8.00pm	Welcome Reception & Poster Viewing Evening in Exhibition and Poster Area, Auckland Rooms, Level 4

TUESDAY 11 SEPTEMBER							
7.00am	Registration, Level 5						
7.30am-9.00am	Satellite Session: BMS Symposium: A Commitment to Liver Health						
	Room: New Zealand 3 and 4 Chair: William Sievert						
7.30am	Breakfast Served until 7.45am						
8.00am-8.05am	Opening remarks from the chair Professor William Sievert, Director, Gastroenterology and Hepatology, Monash Medical Centre, Melbourne, VIC, Australia						
8.05am-8.25am	Hepatitis C treatment beyond interferon Professor Ed Gane, Deputy Director, New Zealand Liver Transplant Unit, Auckland, New Zealand						
8.25am-8.55am	New insights: potent oral antiviral therapy for HBV Dr James Y.Y. Fung, Specialist, Gastroenterology and Hepatology, Transplant Hepatologist, Department of Medicine, Queen Mary Hospital, Hong Kong						
8.55am-9.00am	Closing remarks from the chair Professor William Sievert						
9.00am-10.30am	Conference Plenary: 3						
	Room: New Zealand 1 and 2 Chairs: Stephen Locarnini and Sue Mason						
9.00am-9.30am	Primer to the Future Treatment of HCV Dr Jordan Feld, Assistant Professor of Medicine, University of Toronto Hepatologist, Toronto Western Hospital Liver Centre Scientist, Sandra Rotman Centre for Global Health, Toronto, Canada						
9.30am-10.00am	Development and application of an in vitro system to investigate protease inhibitor susceptibility and resistance development in HCV genotypes 1-6 Professor Peter Simmonds, Professor of Virology, Centre for Infectious Diseases, University of Edinburgh, Edinburgh, Scotland						
10.00am-10.30am	Changing landscape for Hepatitis C pathway Ms Janet Catt, Lead Nurse Specialist Practice, Royal Free Hospital, London, England						
10.30am-11.00am	Morning Tea in Exhibition and Poster Area, Auckland Rooms, Level 4						
11.00am-12.30pm	Proffered Paper Session: Clinical Care: Strategies for expanded access to viral hepatitis assessment and treatment	11.00am-12.30pm	Proffered Paper Session: Epidemiology, Public Health and Prevention: Hepatitis B and liver cancer: Burden of disease and systematic responses	11.00am-12.30pm	Proffered Paper Session: Community and Social Research: Reflecting on Prevention and the Role of Peers	11.00am-12.30pm	Cross Theme Rapid Poster Session
	Room: New Zealand 1 Chairs: Anouk Dev and Sally Spruce		Room: New Zealand 2 Chairs: Susan Carruthers and Stephen Locarnini		Room: New Zealand 3 Chair: Fiona Poeder and Tim Rhodes		Room: New Zealand 4 Chairs: Kimberley Page, David Iser and Carla Treloar
11.00am-11.15am	Development of hepatology nursing guidelines - A contemporary, consensus-based guide for hepatology nursing practice in Australia Jacqui Richmond	11.00am-11.15am	Impact of conditional cash transfers on hepatitis B vaccination completion in people who inject drugs: The Hepatitis B Acceptability and Vaccination Incentives Trial (HAVIT) Lisa Maher	11.00am-11.15am	Health promotion, health protection, health rights - It's time to change Sione Crawford	11.00am-11.10am	Epidemiology, Public Health and Prevention: Introduction 1: Willingness to receive treatment for chronic hepatitis c virus infection among people who inject drugs in the opioid substitution setting: The ETHOS Study (Alavi, M)
11.15am-11.30am	Establishment of the Melbourne health integrated hepatitis B service Tracey Cabrie	11.15am-11.30am	The Forgotten Ones: Responding effectively to hepatitis B in remote settings Jack Wallace	11.15am-11.30am	'DULANGIRR GUBBYNIDGEL' NEW BEGINNINGS: Hepatitis C peer education kit Aimee Capper	11.10am-11.15am	2: Population- Attributable risk estimates for risk factors associated with hepatitis B and C in Pakistan, policy implications for pakistan and other South Asian Countries (Ahmed, B)
						11.15am-11.20am	3: Delivery and monitoring of hepatitis B birth dose: Barriers and strategies (Carville, K)
						11.20am-11.25am	4: Planning for viral hepatitis in NSW/Australia at a Medicare Local and Local Health District Level (Crooks, L)

TUESDAY 11 SEPTEMBER

11.30am-11.45am	Can primary health care identify the diverse population living with chronic hepatitis B? Benjamin Cowie	11.30am-11.45am	Universal newborn hepatitis B vaccination in the Northern Territory two decades on: The end of the Australia antigen? Bette Liu	11.30am-11.45am	Its like hiding the vegetables - Engaging young people in safer drug using education Sam Liebelt	11.30am-11.40am 11.40am-11.45am 11.45am-11.50am 11.50am-11.55am	Clinical Care: Introduction 1: Female sex and variations in IL28B are independently associated with spontaneous clearance of acute HCV infection (Grebely, J) 2: Outcomes of a cohort of prisoners with Genotype 1 hepatitis C treated with standard double therapy. We report success rates of >90% (Wake, C and Siddall, D) 3: Use of fibroscan in assessment of chronic hepatitis B virus infection (Lim, TH) 4: HDV testing in Victoria, Australia 2000-2009: Insights into epidemiology and clinical management (MacLachlan, J)
11.45am-12.00pm	Doctors are doing it by themselves: Experience of a hepatitis C virus (HCV) treatment initiation pilot in general practice in New South Wales, Australia Max Hopwood	11.45am-12.00pm	Hepatocellular carcinoma in the Northern Territory – High incidence and mortality, and the need for a screening program Joshua Davis	11.45am-12.00pm	People who inject drugs and hepatitis C projects: Ensuring community control and relevance Sione Crawford and Jeffrey Wegener		
12.00pm-12.15pm	Growing burden of HCV-related advanced liver disease related to enhanced fibroscan-based screening Dianne How-Chow	12.00pm-12.15pm	Markers of hepatitis B infection and immunity in five Aboriginal Community Controlled Health Services, 2009-2011 Mary Ellen Harrod and Dea Thiele	12.00pm-12.15pm	Clinical & Community Collaboration - HCV Treatment and Care in a Drug and Alcohol Services South Australia (DASSA) site Rosalie Altus and Frederick Robertson	12.00pm-12.05pm 12.10pm-12.15pm 12.15pm-12.20pm	Community and Social Research: Introduction 1: Overdose Management: What's this got to do with Hepatitis C? (Wiggins, N) 2: Peer Education in Aboriginal communities (Camillo, L) 3: "It's taken so long to do treatment": A program aimed at engaging people using illicit drugs and living with hepatitis C (Fitzpatrick, K)
12.15pm-12.30pm	Transient elastography for fibrosis staging in patients with chronic hepatitis B, hepatitis C and non-alcoholic fatty liver disease. A single centre experience David Orr	12.15pm-12.30pm	Estimating Hepatitis B treatment uptake in priority Medicare Locals Nicole Allard	12.15pm-12.30pm	The ETHOS cohort peer support project - Peer support for people undertaking hepatitis C treatment in pharmacotherapy settings; What we have learnt and what we can share Sione Crawford and Stephen Musgrove		
12.30pm-2.00pm	Lunch in Exhibition and Poster Area, Auckland Rooms, Level 4						
12.45pm-1.45pm	ALAF Luchtime Symposium: Implementing National and Regional Strategies on HIV/Viral Hepatitis Co-infection in Asia Room: New Zealand 1 Chairs: Stephen Locarnini and Benjamin Cowie			Satellite Session: The e health journey, from you to PCEHR and everything in between Room: New Zealand 4 Chairs: Sean Holmes and Trina Gregory Sean Holmes, program manager NeHTA and Dr Trina Gregory GPs100 community prescriber and NeHTA clinical lead			
12.45pm-12.52pm	Cambodia: Co-infection of HIV and viral hepatitis in Cambodia Dr Samreth Sovannarith, Chief of AIDS Care Unit, National Centre for HIV/AIDS, Dermatology and STD, Ministry of Health of Cambodia, Cambodia						
12.52pm-12.59pm	Indonesia: HIV-hepatitis co-infection management: Experience from Indonesia Professor Dr Samsurijal Djauzi, School of Medicine, University of Indonesia, Indonesian Association of Physicians in AIDS Care, Indonesia						
12.59pm-1.06pm	Lao: HIV and viral hepatitis co-infection in Lao: Experiences of Mahosot and Sethathirath Hospital Dr Prasith Phimmason, Head of HIV Unit, Mahosot Hospital, Ministry of Health of Lao, Lao						
1.06pm-1.13pm	Sri Lanka: An overview of the management of HIV and HIV-hepatitis co-infection in Sri Lanka Dr Ariyaratne Manathunge, Consultant Venereologist, National STD/AIDS Control Programme in Sri Lanka, Sri Lanka						
1.13pm-1.20pm	Thailand: Management of HIV and hepatitis co-infection: Experience from Thailand Associate Professor Thanyawee Puthanakit, HIVNAT, Thai Red Cross AIDS Research Centre and Faculty of Medicine, Chulalongkorn University, Thailand						
1.20pm-1.27pm	Vietnam: Management of HIV/HBV; HIV/HCV and HIV/HBV/HCV co-infection in Viet Nam (2012-2015) Dr Nguyen Van Kinh, Director of National Hospital of Tropical Diseases, President of Vietnam Clinical HIV/AIDS Society, Vietnam						
1.27pm-1.45pm	Discussion						

TUESDAY 11 SEPTEMBER

2.00pm-3.30pm	Symposium Session: Clinical Care: Advanced Liver Disease	2.00pm-3.30pm	Symposium Session: Epidemiology, Public Health and Prevention: Viral hepatitis and ageing	2.00pm-3.30pm	Symposium Session: Community and Social Research: Health Promotion in a Cultural Context	2.00pm-3.30pm	Symposium Session: Basic Science: Host virus interactions
	Room: New Zealand 1 Chairs: William Sievert and David Orr		Room: New Zealand 2 Chairs: Jason Grebely		Room: New Zealand 3 Chairs: Bill Jang and Peter Higgs		Room: New Zealand 4 Chairs: Eric Gowans and Silvana Gaudieri
2.00pm-2.15pm	Management of patients with advanced hepatitis C Geoff McCaughan, Director, AW Morrow Gastro and Liver Unit, Royal Prince Alfred Hospital, Camperdown, Australia	2.00pm-2.25pm	Ageing and continued drug use: what does the future hold? Susan Carruthers, Research Fellow, National Drug Research Institute, Curtin University, WA, Australia	2.00pm-2.25pm	Aboriginal & Torres Strait Islander Injecting Drug Users The impact of culture on injecting practices Fiona Poeder, BBV & STI Program Manager, Australian Injecting and Illicit Drug Users League (AIVL), Canberra, ACT, Australia	2.00pm-2.25pm	Identification of CD8+ T cell epitopes in the hepatitis B virus core gene using phylogenetic analysis William Abbott, Scientific Officer, New Zealand Liver Transplant Unit, Auckland, New Zealand
2.15pm-2.30pm	Management of patients with advanced hepatitis B James Y.Y. Fung, Specialist in Gastroenterology and Hepatology, Transplant Hepatologist, Department of Medicine, Queen Mary Hospital, Hong Kong	2.25pm-2.50pm	'Double jeopardy' - AIVL's investigation of ageing and hepatitis C Jenny Kelsall, Team Leader, BBV Education & Support, Harm Reduction Victoria, VIC, Australia	2.25pm-2.50pm	Where's the Shame, Love Your Liver! Shame surrounds hep C but we need to talk about it Michelle Cutmore, Registered Nurse, Aboriginal Hepatitis Access and Treatment Coordinator, New South Wales Health, Hunter New England Local Health District, Population Health, Wallsend, NSW, Australia Harpreet Kalsi, Campaigns Coordinator, Aboriginal Health and Medical Research Council of NSW, Sydney, NSW, Australia	2.25pm-2.50pm	Hepatitis C virus and liver lipid metabolism – Novel targets for antiviral treatment Mark Douglas, Senior Lecturer, Storr Liver Unit and Centre for Infectious Diseases and Microbiology, Westmead Millennium Institute, University of Sydney, Sydney, NSW, Australia
2.30pm-2.45pm	Can we prevent cirrhosis complications with antiviral treatment Henry Chan, Director, Cheng Suen Man Shook Centre for Hepatitis Research. Director, Center for Liver Health, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong	2.50pm-3.15pm	Barriers and enablers to effective management of people with chronic hepatitis B Naomi Ngo, Research Fellow, Australian Research Centre in Sex, Health & Society, La Trobe University, VIC, Australia	2.50pm-3.15pm	"Ma Wai e Taurima?" ("Who's looking after the Marae?") Natana Horua, Maori Health Promoter, Hepatitis C Resource Centre, Te Waipounamu, New Zealand	2.50pm-3.15pm	Interferon non-response: New pieces to a very complicated puzzle Jordan Feld, Assistant Professor of Medicine, University of Toronto Hepatologist, Toronto Western Hospital Liver Centre Scientist, Sandra Rotman Centre for Global Health, Toronto, Canada
2.45pm-3.00pm	Nurse led follow up clinic for patients with stable cirrhosis Janet Catt, Lead Nurse Specialist Practice, Royal Free Hospital, London, England	3.15pm-3.30pm	Discussion	3.15pm-3.30pm	Discussion	3.15pm-3.30pm	Discussion
3.00pm-3.30pm	Panel Discussion Geoff McCaughan, James Y.Y. Fung, Henry Chan, Janet Catt						
3.30pm-4.00pm	Afternoon Tea in Exhibition and Poster Area, Auckland Rooms, Level 4						

TUESDAY 11 SEPTEMBER

4.00pm-5.30pm	Proffered Paper Session: Clinical Care: New directions in treatment monitoring and delivery	4.00pm-5.30pm	Proffered Paper Session: Epidemiology, Public Health and Prevention: New horizons: modelling, linkage and registry studies in viral hepatitis	4.00pm-5.30pm	Proffered Paper Session: Community and Social Research: Engaging Communities	4.00pm-5.30pm	Proffered Paper Session: Basic Science: Hepatitis infections: Control and prevention
	Room: New Zealand 1 Chairs: Jordan Feld and Geoff McCaughan		Room: New Zealand 2 Chairs: Christine Selvey and Josh Davis		Room: New Zealand 3 Chairs: Jack Wallace and Paul Ward		Room: New Zealand 4 Chairs: Scott Bowden and John Taylor
4.00pm-4.15pm	The DAA development race - Innovative ways of getting to POC quickly Nicky Cranshaw	4.00pm-4.15pm	Impact of hepatitis C virus infection on life expectancy: A population-based linkage study Maryam Alavi	4.00pm-4.15pm	'Our C-Ciety': The targets and challenges of social media Fiona Poeder	4.00pm-4.15pm	PPARα agonists increase interferon sensitivity and may be an effective supplementary treatment for difficult to treat patients with hepatitis C Mark Douglas
4.15pm-4.30pm	ELECTRON: Once-daily GS-7977 plus ribavirin for 12 weeks provides SVR without interferon in treatment-naive and experienced HCV GT 1/2/3 Edward Gane	4.15pm-4.30pm	Most hepatitis c reinfections that clear spontaneously go undetected – Bayesian analysis of a prospective longitudinal study Rachel Sacks-Davis	4.15pm-4.30pm	Empowering, skilling and equipping C- Me community champions to represent their communities' voice, have it heard and access the services they need David Pieper	4.15pm-4.30pm	Screening of ISGs reveals viperin and the IFITM family of proteins to be novel anti-HCV effectors Michael Beard
4.30pm-4.45pm	Patterns of HCV RNA during acute hepatitis C virus infection guide optimum timing for therapeutic intervention Behzad Hajarizadeh	4.30pm-4.45pm	Liver cancer in Victoria, Australia: Epidemiological determinants and secular and geographic trends 1982-2007 Kylie Carville	4.30pm-4.45pm	Using theatre to break down the barriers: a Partnership approach to Hepatitis C Awareness Lauren Proudfoot	4.30pm-4.45pm	Immune responses against founder hepatitis C viruses in acute asymptomatic subjects Fabio Luciani
4.45pm-5.00pm	Impact of treatment on injecting drug use behaviours during recent HCV infection Jason Grebely	4.45pm-5.00pm	Modelling new HCV antiviral treatments for prevention of HCV among people who inject drugs: a multi-country analysis of impact Natasha Martin	4.45pm-5.00pm	Finding voices for hepatitis B in Australia Yvonne Drazic and Linh Nguyen	4.45pm-5.00pm	HCV specific CD8+ T cell targets show limited ability to generate cross-genotype responses Pooja Deshpande
5.00pm-5.15pm	Australian Trial in Acute Hepatitis C (ATAHC) II Study Gail Matthews	5.00pm-5.15pm	What's in a name? Evaluation of a novel screening tool for identifying overseas-born primary care patients at risk of chronic hepatitis B Jennifer MacLachlan	5.00pm-5.15pm	The role of General Practitioners in managing patients with chronic hepatitis B Jacqui Richmond	5.00pm-5.15pm	Utility of next-generation sequencing for Hepatitis B virus genotyping and detection of antiviral resistance Fahimeh Rahnama
5.15pm-5.30pm	Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B (CHB) with entecavir (ETV) monotherapy or ETV plus tenofovir (TDF) in the BE-LOW study Cyril Llamoso	5.15pm-5.30pm	An assessment of the cost-effectiveness of treating chronic HCV infection among People Who Inject Drugs in Victoria, Australia Margaret Hellard	5.15pm-5.30pm	To B or not to B - That is the question Annie Madden	5.15pm-5.30pm	A second generation therapeutic cellular vaccine for hepatitis C virus Eric Gowans
7.00pm	Conference Dinner, Voyager Maritime Museum, Auckland Viaduct Harbour						

WEDNESDAY 12 SEPTEMBER

7.30am	Registration, Level 5	
8.30am-10.00am	Cross Track Symposium Session: Treatment as prevention of liver cancer Sponsored by: Cancer Council of Victoria Room: New Zealand 1 and 2 Chair: Benjamin Cowie and Joshua Davis	8.30am-10.00am Cross Track Symposium Session: What can research with people who inject drugs tell us about how to avoid hepatitis C in the long-term?: Next generation hepatitis C prevention strategies Room: New Zealand 3 and 4 Chair: Lisa Maher
8.30am-8.45am	Increasing burden of hepatocellular carcinoma in Australia and New Zealand Greg Dore, Kirby Institute for infection and immunity in society, The University of New South Wales, NSW, Australia	8.30am-8.35am Background for Staying Safe Research: Using positive deviance research methods to discover new approaches to epidemiology and prevention Sam Friedman, Director of HIV/AIDS Research, National Development and Research Institutes, New York, USA
8.45am-9.05am	What are the current perceptions about the link between liver cancer and chronic hepatitis B in Australia's Chinese and Vietnamese communities? Zhihong Gu, Program Manager, Ethnic Communities Council of Queensland (ECCQ), West End, QLD, Australia Emily Adamson, Hepatitis B Program Coordinator, Cancer Council Victoria, Carlton, Victoria, Australia	8.35am-8.50am Staying Safe London: Indirect technologies of HCV prevention Magdalena Harris, Centre for Research on Drugs and Health Behaviour, London School of Hygiene and Tropical Medicine, London, UK
9.05am-9.20am	What is the evidence for the clinical efficacy of hepatitis B treatment in preventing liver cancer? Henry Chan, Director, Cheng Suen Man Shook Centre for Hepatitis Research. Director, Center for Liver Health, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong	8.50am-9.05am Staying Safe Sydney: The logic of care and trust in hepatitis C testing Carla Treloar, Deputy Director, National Centre In HIV Social Research, Sydney, NSW, Australia
9.20am-9.35am	What is the evidence for the cost effectiveness of hepatitis B treatment in preventing liver cancer? Monica Robotin, Medical Director, Cancer Council NSW, NSW, Australia	9.05am-9.20am Strategies long term injectors use to avoid HCV infection Peter Higgs, Post Doctoral Fellow, Kirby Institute, Darlinghurst, NSW, Australia
9.35am-10.00am	Discussion	9.20am-9.35am Staying Safe Intervention: Training injection drug users in strategies to avoid HCV and HIV injection-related infections Sam Friedman, Director of HIV/AIDS Research, National Development and Research Institutes, New York, USA
		9.35am-9.50am Vein care as a blood borne virus prevention strategy - An interactive online resource Sam Liebelt, Communications Coordinator, Australian Injecting and Illicit Drug Users League (AIVL), Canberra, ACT, Australia
		9.50am-10.00am Discussion
10.00am-10.30am	Morning Tea in Exhibition and Poster Area, Foyer, Level 5	
10.30am-12.00pm	Cross Track Symposium Session: Treatment as prevention of HCV transmission Room: New Zealand 1 and 2 Chairs: John Hornell and Charles Henderson	10.30am-12.00pm Cross Track Symposium Session: Co-infection Room: New Zealand 3 and 4 Chairs: Edward Gane and Julie Bruneau
10.30am-10.45am	Reducing HCV in people who inject drugs: Total coverage, test, tell and targeted treatment Margaret Hellard, Centre Head, Centre For Population Health, Burnet Institute, Melbourne, VIC, Australia	10.30am-10.45am HCV transmission among men who have sex with men Joe Sasadeusz, Associate Professor, Royal Melbourne and Alfred Hospitals, Melbourne, VIC, Australia
10.45am-11.00am	Modeling the impact of HCV treatment on transmission Natasha Martin, University of Bristol; London School of Hygiene and Tropical Medicine, UK	10.45am-11.00am Impact of HIV and HBV co-infection on morbidity and mortality among people with HCV Janaki Amin, Biostatistics and database program, The Kirby Institute, NSW, Australia
11.00am-11.15am	Keeping the individual central to HCV prevention, treatment and care Sione Crawford, Director, Community Programs & Services, NSW Users and AIDS Association (NUAA), Surry Hills, NSW, Australia	11.00am-11.20am Therapeutic strategies for HIV/HCV co-infection Gail Matthews, Senior Lecturer, Viral Hepatitis Clinical Research Program, The Kirby Institute, NSW, Australia
11.15am-11.30am	HCV treatment as prevention: Key components for feasibility Greg Dore, Kirby Institute for infection and immunity in society, The University of New South Wales, NSW, Australia	11.20am-11.40am Therapeutic strategies for HBV HCV dual infection David Iser, Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia
11.30am-12.00pm	Discussion	11.40am-12.00pm Discussion
12.00pm-12.30pm	Closing Plenary	
	Room: New Zealand 1 and 2 Chairs: Greg Dore and Carla Treloar	
12.00pm-12.30pm	Conference Wrap-Up and Close	
	Greg Dore and Carla Treloar	
12.30pm	Conference Close	